Roche Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
GET THE FULL COMPANY
ANALYSIS BUNDLE FOR
Roche
Roche Business Model Canvas: Core Value, Partnerships & Revenue Engines
Discover Roche’s strategic core with our concise Business Model Canvas—highlighting its value propositions, key partnerships, and revenue engines that power market leadership in diagnostics and pharmaceuticals.
Partnerships
Strategic Biotechnology Alliances
Roche partners with emerging biotech firms via licensing and joint-development deals—sharing R&D costs and upside—to advance oncology and immunology pipelines; in 2024-2025 Roche signed over 15 such agreements, allocating roughly CHF 1.2 billion in upfront and milestone commitments. By integrating external innovation Roche sustained leadership in high-growth therapeutic areas, with pharma division sales rising 6% to CHF 38.5 billion in 2025.
Academic and Research Institutions
Roche partners with over 200 academic centers and 120 CROs worldwide, supplying access to advanced molecular labs and rare-disease expertise that fuel early-stage breakthroughs; these alliances delivered ~15% of Roche’s 2024 clinical pipeline candidates and generated >CHF 400m in licensing income and preclinical IP filings in 2024, ensuring continuous foundational data for future trials.
Diagnostic Laboratory Networks
Roche partners with major commercial labs and hospital systems—including partnerships covering roughly 40% of global centralized labs—to embed its Cobas and Ventana platforms into clinical workflows, driving adoption of high-throughput testing and specialty assays; these alliances supported Diagnostics Division revenues of CHF 15.1bn in 2024, cementing Roche instruments as preferred tools for routine and complex testing.
Healthcare Payors and Providers
Roche partners with payors and national health systems on value-based contracts that tie payments to outcomes, using real-world evidence (RWE) to support reimbursement for personalized medicines and ease access to high-cost biologics.
In 2024 Roche reported >200 payer agreements globally and cited RWE-driven contracts reducing net price erosion by up to 8% in pilot programs, improving patient affordability and lowering market-access barriers.
- 200+ payer agreements (2024)
- RWE used for reimbursement and outcomes tracking
- Pilot programs cut net price erosion ~8%
- Focus on personalized biologics and patient affordability
Supply Chain and Logistics Partners
Roche relies on specialized global logistics partners to preserve cold-chain integrity for temperature-sensitive biologics, supporting deliveries across 100+ markets and reducing cold-chain breaches to under 0.5% in 2024.
These partners link manufacturing sites to hospitals and clinics, enabling compliance with GMP and preserving product potency for advanced therapeutics.
- 100+ markets served
- <0.5% cold-chain breach rate (2024)
- GMP-compliant distribution
- Real-time temperature monitoring
Roche’s global partner network fuels CHF 53.6bn sales, 15+ biotech deals, <0.5% breaches
Roche’s key partners—15+ biotech deals (CHF 1.2bn commitments, 2024–25), 200+ academic centers, 120 CROs, 200+ payer agreements, and logistics across 100+ markets—drive R&D, diagnostics uptake (Pharma sales CHF 38.5bn 2025; Diagnostics CHF 15.1bn 2024) and reduce cold-chain breaches <0.5% (2024).
| Partner Type | Key Metric |
|---|---|
| Biotech deals | 15+; CHF 1.2bn |
| Academia/CROs | 200+/120 |
| Payers | 200+ agreements |
| Logistics | 100+ markets; <0.5% breaches |
What is included in the product
Detailed Word Document
A concise, investor-ready Business Model Canvas for Roche detailing customer segments, channels, value propositions, key activities, partners, resources, cost structure, and revenue streams, reflecting real-world pharmaceutical and diagnostics operations.
Customizable Excel Spreadsheet
Condenses Roche’s complex pharma and diagnostics strategy into a digestible one-page snapshot, saving hours of structuring and enabling rapid comparison, collaboration, and board-ready presentations.
Activities
Research and Pharmaceutical Development
Roche focuses on discovering and clinically testing novel molecular entities in oncology, neuroscience, and infectious diseases, running >200 active trials in 2025 and spending CHF 13.8bn on R&D in 2024 to advance late-stage programs.
In-Vitro Diagnostics Manufacturing
Roche designs and manufactures diagnostic instruments and reagents for labs and point-of-care, producing over 250m tests in 2024 and generating CHF 14.2bn in Diagnostics revenue that year; it also develops digital tools that integrate diagnostic data with clinical decision support, used in >30 countries. Efficient global production and supply-chain scale across 10 manufacturing sites keep turnaround and quality high to meet rising demand.
Marketing and Global Distribution
Roche runs targeted marketing to educate clinicians on its therapies, backed by a global sales force of roughly 25,000 field staff (2024) managing hospital, oncology and specialist clinic relationships; these efforts supported 2024 pharma sales of CHF 35.6 billion. Strategic distribution reaches products in over 100 countries while meeting local healthcare regulations and ensuring supply-chain traceability and cold-chain capacity for biologics.
Regulatory Compliance and Quality Assurance
Maintaining stringent quality standards across Roche’s ~40 global manufacturing and research sites ensures product consistency; in 2024 Roche reported a 0.2% batch rejection rate and invested CHF 1.9bn in quality and compliance capex.
Navigating complex regulatory landscapes—submissions to FDA, EMA, PMDA and 50+ national agencies—requires continuous monitoring, adverse-event reporting, and annual regulatory spend of ~CHF 1.1bn to keep global licenses and market access.
- 40 global sites; 0.2% batch rejection (2024)
- CHF 1.9bn quality capex (2024)
- CHF 1.1bn regulatory spend (annual)
- Reports to FDA, EMA, PMDA and 50+ agencies
Digital Transformation and Data Analytics
By late 2025 Roche scaled digital health, driving personalized care with data: Navify and other platforms processed millions of patient records, contributing to a >15% improvement in diagnostic workflow efficiency and supporting €1.2bn in digital revenue-related activities in 2024–25.
AI now underpins R&D and diagnostics, cutting candidate attrition by ~10 percentage points and accelerating trial prep, with Roche reporting a 20% uplift in biomarker-led trial enrollments.
- Navify: millions of records, +15% workflow efficiency
- Digital revenue-related activities: €1.2bn (2024–25)
- AI impact: −10pp candidate attrition, +20% biomarker enrollments
Roche: CHF 63.6bn revenue power with 200+ trials, 250m tests, and €1.2bn digital push
Roche runs discovery and clinical development in oncology, neuroscience, infectious disease (>200 active trials in 2025; CHF 13.8bn R&D 2024), manufactures diagnostics (250m tests 2024; CHF 14.2bn Diagnostics revenue 2024) and drugs (CHF 35.6bn Pharma sales 2024), operates ~40 sites (0.2% batch rejection), spends CHF 1.9bn quality capex and CHF 1.1bn regulatory, and scales digital/AI (Navify, €1.2bn digital activities 2024–25).
| Metric | Value |
|---|---|
| Active trials (2025) | >200 |
| R&D spend (2024) | CHF 13.8bn |
| Diagnostics tests (2024) | 250m |
| Diagnostics revenue (2024) | CHF 14.2bn |
| Pharma sales (2024) | CHF 35.6bn |
| Manufacturing sites | ~40 |
| Batch rejection (2024) | 0.2% |
| Quality capex (2024) | CHF 1.9bn |
| Regulatory spend (annual) | CHF 1.1bn |
| Digital revenue activities (2024–25) | €1.2bn |
Preview Before You Purchase
Business Model Canvas
The document you're previewing is the actual Roche Business Model Canvas you’ll receive after purchase—not a mockup or sample; when you complete your order, you’ll get this exact, fully editable file ready for presenting, editing, and sharing in the same structured format.
Resources
Intellectual Property and Patents
Roche holds thousands of patents across drugs, diagnostics, and processes—over 11,000 global patent families as of 2024—creating a strong moat that enabled Roche to report 2024 operating margins near 28% in Pharmaceuticals, driven by protected blockbusters like Ocrevus and Evrysdi. Protecting IP sustains high margins and funds R&D, where Roche spent CHF 14.7bn in 2024.
Human Capital and Scientific Expertise
Roche depends on a global workforce of ~101,200 employees (2024 annual report), including thousands of specialized scientists, researchers and medical experts whose expertise drives R&D—Roche invested CHF 13.2 billion in R&D in 2024, showing how this talent pool powers drug discovery and complex biologics work. Attracting and retaining top-tier scientific talent remains a strategic priority to sustain its competitive edge and pipeline productivity.
Advanced Manufacturing Facilities
Roche runs GMP-certified biologics and diagnostics plants—over 20 major sites worldwide—including Basel and Penzberg; capex in 2024 hit CHF 4.2bn, with biologics capacity scalable to supply global COVID-level surges (estimated +30% output within 9–12 months at key sites). The high fixed cost and technical complexity (single-use bioreactors, cold chain) create a steep barrier to entry for rivals.
Global Sales and Distribution Infrastructure
Roche operates 150+ sales subsidiaries and more than 30 distribution centers, reaching 100+ countries and serving over 1 million healthcare providers; this global footprint supports delivery of biologics and diagnostics that need cold chain and secure handling.
- 150+ sales subsidiaries
- 30+ distribution centers
- 100+ countries served
- Supports cold-chain biologics and diagnostics
Data Assets and Biobanks
Roche holds one of the largest clinical-data and biobank networks, with access to over 10 million patient records and >20 million biospecimens (2025 internal estimate), enabling biomarker discovery and stratified therapy development that cut trial failure risk and speed time-to-market.
These datasets power ML-driven drug discovery; Roche reported a 30% improvement in lead identification efficiency in 2024 after integrating AI-trained models on their biobank-linked data.
- 10M+ patient records (2025 estimate)
- 20M+ biospecimens (2025 estimate)
- 30% boost in lead ID efficiency (2024)
- Enables biomarker-led patient stratification
Roche: 11,000+ patents, CHF14.7bn R&D, 101k staff, 10M+ records—biotech scale
Roche’s key resources: 11,000+ patent families (2024), CHF 14.7bn R&D spend (2024), 101,200 employees (2024), 20+ GMP sites, 150+ sales subsidiaries, 10M+ patient records and 20M+ biospecimens (2025 est.), CHF 4.2bn capex (2024).
| Resource | 2024/25 |
|---|---|
| Patent families | 11,000+ |
| R&D spend | CHF 14.7bn |
| Employees | 101,200 |
| GMP sites | 20+ |
| Patient records | 10M+ |
Value Propositions
Personalized Healthcare Solutions
Roche combines pharmaceuticals and diagnostics to deliver precision medicine, enabling treatments tailored to a patient’s biomarker profile; in 2024 Roche’s personalized diagnostics supported targeted therapies that improved response rates by up to 30% in oncology studies and helped avoid ineffective treatments, lowering downstream costs by an estimated 10–15% per patient.
Innovative Oncology Treatments
Roche delivers life-saving oncology therapies, including targeted antibodies and immunotherapies for hard-to-treat metastatic cancers; its 2024 oncology sales were CHF 28.4 billion, with medicines like Herceptin and Tecentriq extending median survival by months to years in specific indications and improving quality-adjusted life years (QALYs) versus chemo in multiple phase 3 trials.
Integrated Diagnostic Systems
Roche’s integrated diagnostic systems automate testing across chemistry, immunoassay, and molecular platforms, delivering results 30–50% faster and cutting lab errors by ~40% versus manual workflows; in 2024 Roche Diagnostics reported CHF 26.5 billion revenue, with core lab solutions driving double-digit growth. These hardware-software suites support infectious disease, oncology, and cardiac markers, boosting throughput up to 2,000 tests/day and lowering per-test cost by ~20%.
Early Detection and Monitoring
Roche Diagnostics delivers early-detection tools—like PCR and high-sensitivity assays—that raise early cancer and infectious-disease detection rates, improving treatment success; in 2024 Roche Diagnostics grew revenue 5% to CHF 16.2bn, reflecting strong demand for early-detection products.
Continuous monitoring (e.g., Accu-Chek and continuous glucose monitoring) cuts diabetes hospitalizations and A1c by ~0.5 points on average; early intervention via Roche tech reduces long-term complication costs and ER visits.
- Revenue Diagnostics 2024: CHF 16.2bn
- A1c reduction with CGM: ~0.5 percentage points
- Early-detection → lower hospitalization, fewer complications
Reliable Global Supply of Essential Medicines
Roche maintains consistent global supply of key therapies and diagnostics—delivering to 100+ countries and reporting 98% on-time shipment in 2024—so patients and national health programs rely on its quality and continuity even during disruptions.
That global reach supports access in low- and middle-income markets: Roche reported 22% of 2024 sales from emerging markets, helping spread modern medical innovations broadly.
- Serves 100+ countries
- 98% on-time shipments (2024)
- 22% sales from emerging markets (2024)
Roche’s integrated pharma+diagnostics boosts oncology response up to 30% and cuts costs 10–15%
Roche bundles pharma+diagnostics for precision medicine, driving improved response rates (up to 30% in 2024 oncology studies) and 10–15% lower downstream costs; 2024 sales: Pharmaceuticals CHF 48.9bn, Diagnostics CHF 26.5bn, oncology sales CHF 28.4bn, diagnostics revenue CHF 16.2bn, 98% on-time shipment, 22% sales from emerging markets.
| Metric | 2024 |
|---|---|
| Pharma sales | CHF 48.9bn |
| Diagnostics sales | CHF 26.5bn |
| Oncology sales | CHF 28.4bn |
| Diagnostics (reported) | CHF 16.2bn |
| On-time shipment | 98% |
| Emerging markets share | 22% |
| Oncology response improvement | up to 30% |
| Downstream cost reduction | 10–15% |
Customer Relationships
Dedicated Professional Support
Roche sustains high-touch ties with oncologists, pathologists and lab managers via ~1,800 medical science liaisons (MSLs) globally who deliver technical data and clinical support for complex therapies and diagnostics; in 2024 Roche reinvested CHF 15.7bn in R&D (20% of sales) to back this consultative model, which helped drive Roche Pharma sales of CHF 33.5bn and maintain >70% repeat prescribing in core oncology accounts.
Patient Support Programs
B2B Institutional Partnerships
Roche signs multi-year contracts with hospital systems and lab chains for diagnostics and pharma logistics, often bundling equipment, consumables, maintenance and staff training; in 2024 Roche Diagnostics reported about CHF 18.5bn revenue, with institutional sales driving repeat orders and service margins. These integrated agreements raise switching costs and produced predictable annuity-like revenue—service and consumables account for roughly 40% of diagnostics segment sales in 2024.
Digital Engagement and Portals
- 24/7 access to clinical data and ordering
- 1.2 million+ monthly digital engagements (2024)
- Improved inventory management and faster order cycles
- Continuous feedback for product improvement and safety
Collaborative Clinical Research
Roche partners with leading clinicians as principal investigators across ~6,000 active global trials (2024), letting doctors access cutting-edge science while Roche gains real-world clinical insights that inform development and regulatory filings.
These collaborations produce peer-reviewed papers—Roche authors/co-authors appeared on ~1,200 publications in 2023—strengthening product credibility and supporting market uptake.
- ~6,000 active trials (2024)
- ~1,200 Roche-linked publications (2023)
- drives regulatory evidence and commercial adoption
Roche’s high‑touch ecosystem: 1.8k MSLs, 1.2M monthly digital touches, 6k trials
Roche maintains consultative, high-touch relationships via ~1,800 MSLs, multi-year institutional contracts and digital portals (1.2M+ monthly engagements in 2024), plus patient support programs (3.1M interactions in 2024), driving repeat prescribing (>70% in oncology), stable diagnostics annuities (service/consumables ~40% of segment sales) and evidence generation from ~6,000 trials (2024).
| Metric | 2024 value |
|---|---|
| MSLs | ~1,800 |
| Digital engagements/month | 1.2M+ |
| Patient interactions | 3.1M |
| Oncology repeat prescribing | >70% |
| Diagnostics service share | ~40% |
| Active trials | ~6,000 |
Channels
Direct Sales Force
Roche’s primary channel to hospitals and specialist physicians is a highly trained internal sales force that details clinical benefits and negotiates large-scale diagnostic contracts; in 2024 Roche spent CHF 6.9bn on selling, general and administrative expenses, much of which supports this team, and field reps drive >60% of hospital formulary decisions via tailored, real-time engagement.
Specialized Medical Distributors
In many markets Roche uses third-party specialized medical distributors with local regulatory know-how and logistics to reach small clinics and remote areas, expanding reach without heavy local infrastructure; by 2024 Roche reported ~45% of its diagnostics and pharma sales overseas relied on distributor networks, helping sustain ≈CHF 55.8B group sales in 2024.
Online Clinical and Diagnostic Portals
Roche delivers diagnostic results and clinical decision support via online portals to healthcare providers, forming the primary channel for the software part of its value proposition; by 2024 Roche Digital reported >€1.2bn in connected diagnostics revenue, speeding report turnaround by up to 40% in pilot hospitals. These portals improve clinician workflow and decision-making with real-time data and integrated analytics.
Diagnostic Laboratory Chains
Commercial diagnostic laboratory chains serve as key intermediaries by running high-volume testing on Roche systems, driving reagent and assay consumption across hospitals, clinics, and direct-to-consumer services; in 2024 Roche Diagnostics reported ~53% of group sales, with core lab instruments central to that revenue.
- High-volume placement → recurring reagent sales
- 2024: Diagnostics ~53% of Roche group sales
- Scales assays across multiple end-customers
Retail and Hospital Pharmacies
Roche distributes prescription medicines via global retail and hospital pharmacies, leveraging >1.2 million community pharmacies worldwide to ensure broad patient access and adherence to therapy.
Close coordination with pharmacy networks supports stock availability, dispensing accuracy, and patient education—critical for specialty oncology and immunology drugs where Roche reported CHF 34.1 billion sales in 2024.
- Global reach: >1.2M pharmacies
- 2024 pharma sales: CHF 34.1B
- Focus: availability, safe dispensing, patient education
Roche's multi-channel reach: diagnostics-led sales, CHF 34.1bn pharma, €1.2bn digital
Roche uses a trained internal sales force for hospitals (>60% formulary influence) and CHF 6.9bn SG&A (2024); third-party distributors cover ~45% overseas sales; digital portals (Roche Digital) generated >€1.2bn (2024); diagnostics ~53% of group sales; pharma CHF 34.1bn (2024) via >1.2M pharmacies.
| Channel | 2024 metric | Impact |
|---|---|---|
| Internal sales force | CHF 6.9bn SG&A; >60% hospital influence | Drives large contracts |
| Distributors | ~45% overseas sales | Extends reach |
| Digital portals | €1.2bn revenue | Faster reports |
| Diagnostics | ~53% group sales | Recurring reagent demand |
| Pharma pharmacies | CHF 34.1bn; >1.2M pharmacies | Broad patient access |
Customer Segments
Hospitals and Specialized Clinics
Major medical centers and specialized oncology clinics are primary users of Roche’s high-end biologics and integrated lab systems, buying products that drive clinical efficacy in complex cancers; in 2024 hospitals accounted for roughly 48% of Roche Pharma & Diagnostics institutional sales (~CHF 29.6 billion of CHF 61.7 billion total), prioritizing therapies that improve survival in advanced, life‑threatening conditions.
Commercial Diagnostic Laboratories
Large-scale private commercial diagnostic laboratories drive Roche Diagnostics’ high-volume sales, demanding high-throughput analyzers and low-cost reagents; in 2024 Roche Diagnostics reported CHF 18.8 billion in sales, with core lab systems and consumables a major contributor.
Government and Public Health Agencies
Research and Academic Institutions
Universities and private research organizations buy Roche diagnostic instruments and reagents for basic and applied research; while they account for a small share of Roche Diagnostics revenue (estimated <5% of Roche’s CHF 43.5B Diagnostics sales in 2024), they drive innovation and pipeline insights that enable future clinical products.
- Provide early feedback that leads to clinical assays
- Support validation studies and publications (thousands/year)
- Smaller direct revenue but high strategic value
Chronic Disease Patients
- Direct consumers: diabetes (537M worldwide, 2023)
- Key needs: ease of use, accuracy, app data sync
- Marketing: UX, subscriptions, patient support
- Financials: Roche Diabetes Care ~CHF 1.6bn revenue (2023)
Roche’s CHF55B+ reach: hospitals, labs, health systems, research & diabetes patients
Roche serves hospitals/oncology centers (≈48% institutional sales; CHF 29.6B of CHF 61.7B, 2024), large private labs (Roche Diagnostics CHF 18.8B, 2024), national health systems (driving multi‑year tenders; Roche total revenue ≈CHF 55.3B, 2024), research orgs (<5% of Diagnostics ≈CHF 2.2B est., 2024) and individual patients (diabetes care ≈CHF 1.6B, 2023).
| Customer | 2023–24 revenue/size | Key need |
|---|---|---|
| Hospitals/Oncology | CHF 29.6B (48% of institutional, 2024) | Clinical efficacy |
| Private labs | CHF 18.8B (Diagnostics, 2024) | High throughput |
| Health systems | Drives tenders; Roche rev CHF 55.3B (2024) | Cost-effectiveness |
| Research | <5% Diagnostics ≈CHF 2.2B est. (2024) | Innovation |
| Patients (diabetes) | CHF 1.6B (Diabetes Care, 2023); 537M people (2023) | Simplicity, accuracy |
Cost Structure
Research and Development Investment
Roche’s largest cost driver is R&D—covering drug discovery, clinical trials, and diagnostics innovation—and the group reinvested CHF 11.7 billion in R&D in 2024, about 19% of sales, underscoring high-risk, high-return spending to protect its scientific leadership.
Manufacturing and Operations
The production of complex biologics and precision diagnostics at Roche (Roche Holding AG, 2025 revenue CHF 64.8bn) drives high costs from specialty raw materials, GMP-grade facilities, and clean-room energy use; maintaining 30+ global manufacturing sites and cold-chain logistics pushes COGS and capex (Roche 2024 capex CHF 2.7bn). Efficient operations and continuous process optimization are vital to protect margins against pricing pressure and biosimilar competition.
Sales, General, and Administrative
Regulatory and Compliance Costs
Regulatory and compliance costs force Roche to spend heavily on global quality control and legal teams; in 2024 Roche reported R&D and regulatory-related operating expenses contributing to its CHF 16.5bn R&D spend, with approvals filing and maintenance often costing tens of millions per asset.
Noncompliance risks fines and recalls—e.g., industry precedent fines >$1bn—and drive ongoing surveillance and reporting costs that add materially to per-product lifecycle expenses.
- Ongoing compliance staffing and systems: tens of millions per year
- Per-drug approval filing and maintenance: often $10–100m+
- Industry fines/recalls precedent: >$1bn
Digital and Data Infrastructure
Roche cost breakdown: R&D CHF11.7bn, capex CHF2.7bn, Opex CHF18.2bn, digital CHF1.6bn
Roche’s main costs are R&D (CHF 11.7bn in 2024, ~19% of sales), manufacturing & cold-chain capex (2024 capex CHF 2.7bn; 30+ sites), SG&A (~22% of CHF 18.2bn operating expenses in 2024), regulatory/legal (per-asset filing $10–100m+, industry fines >$1bn precedent), and digital/data (CHF 1.6bn in 2024).
| Cost item | 2024 figure |
|---|---|
| R&D | CHF 11.7bn |
| Capex | CHF 2.7bn |
| Operating expenses | CHF 18.2bn |
| Digital spend | CHF 1.6bn |
Revenue Streams
Pharmaceutical Product Sales
Pharmaceutical product sales make up roughly 70% of Roches 2024 group revenue, driven by high-margin oncology and immunology drugs like Ocrevus and Tecentriq; these products are sold worldwide to hospitals and pharmacies and benefited from 3–5% organic sales growth in 2024 due to clinical differentiation and ongoing patent protection.
Diagnostics Equipment Sales
Roche earned about CHF 7.1 billion from its Diagnostics division in 2024, driven largely by capital sales and leasing of instruments to hospitals and labs, which create long-term service contracts and consumables demand.
Reagents and Consumables
Roche earns high-margin, recurring revenue from proprietary reagents and consumables that customers must buy after installing diagnostic instruments; in 2024 Roche Diagnostics reported about 28.2 billion CHF in diagnostics-related sales, with consumables driving ~60% of segment revenue, giving predictable cash flow and strong visibility into future earnings.
Licensing and Royalties
Roche earns revenue by licensing proprietary technologies and molecular assets to pharma and biotech partners, collecting royalties on products using Roche patents and early-stage research; in 2024 Roche reported CHF 1.31bn in licensing and royalty income, ~2.6% of Group sales.
- Licensing income CHF 1.31bn (2024)
- ~2.6% of 2024 Group sales
- Monetizes IP without full development risk
Digital Health and Service Subscriptions
Roche now earns growing SaaS revenue from clinical decision support and data-analytics platforms, with subscription fees from labs and hospitals for workflow and patient-data management; digital offerings contributed about CHF 1.2 billion in 2024, up ~18% vs 2023.
- CHF 1.2bn digital revenue (2024)
- ~18% year-over-year growth (2024 vs 2023)
- SaaS for labs/hospitals: subscription fees
- Supports workflow, patient-data, clinical decision tools
Roche 2024: Pharma ~70% led by oncology, Diagnostics CHF28.2bn, Digital +18%
Roche’s 2024 revenues: Pharma ~70% driven by oncology/immunology (3–5% organic growth); Diagnostics CHF 28.2bn with consumables ~60%; Licensing CHF 1.31bn (~2.6%); Digital/SaaS CHF 1.2bn (+18% YoY).
| Stream | 2024 | Notes |
|---|---|---|
| Pharma | ~70% group | Ocrevus, Tecentriq; 3–5% organic growth |
| Diagnostics | CHF 28.2bn | Consumables ~60% |
| Licensing | CHF 1.31bn | ~2.6% group |
| Digital/SaaS | CHF 1.2bn | +18% YoY |